Shares rose modestly by 2.0% following the earnings update as the company highlighted ongoing clinical progress and new trial initiations, though the market showed restraint, indicating results and developments were broadly in line with expectations without clear breakthroughs.

• Presented Phase II clinical data for refractory gastric cancer showing prolonged median overall survival beyond 23 months in a heavily pretreated, checkpoint-refractory patient population.
• Introduced a randomized Phase II trial for severe acute lung injury and ARDS, designed with a seamless Phase II/III pathway to accelerate potential registrational development.
• Highlighted translational findings demonstrating the platform’s mechanistic immune modulation versatility across distinct disease areas including cancer and severe lung injury.
• Announced a strategic collaboration to advance targeted TCR engineered iNKT therapies for pediatric cancers, aiming to leverage off-the-shelf cell therapy advantages in a high-need area.
• Safety profile across approximately 100 patients treated remains favorable with no new red flags noted, supporting continued clinical development.